论文部分内容阅读
目的 探讨雌 /孕激素受体 (ER/PR)在肺癌的临床病理意义 ,研究肺癌的激素受体表达、DNA含量及其与生物学特性的关系。方法 应用免疫组织化学SP法检测肺癌组织ER/PR ,流式细胞仪检测DNA含量。结果 4 0例肺癌ER检测阳性 2 3例 (57.5% ) ,PR检测阳性 16例 (4 0 .0 % ) ,异倍体者 31例 (77.5% ) ;受体阳性率与组织学分级呈负相关 ,并与病理类型有关 ;ER阳性者DI值较低 ,以二倍体多见。结论 肺癌组织中存在雌 /孕激素受体 ,能用以反映其生物学行为 ,联合检测激素受体和DNA含量可为肺癌内分泌治疗和预后评估提供更多的生物学依据
Objective To investigate the clinicopathological significance of estrogen / progesterone receptor (ER / PR) in lung cancer and to study the relationship between hormone receptor expression, DNA content and biological characteristics in lung cancer. Methods Immunohistochemical SP method was used to detect the ER / PR in lung cancer tissues. DNA content was detected by flow cytometry. Results Twenty-four cases (57.5%) were detected positive for ER in lung cancer, 16 cases (40.0%) were detected by PR, 31 cases (77.5%) were aneuploidy, and the positive rate of receptor and histological grade were negative Related, and with the pathological type; ER positive DI value is lower, more common in diploid. Conclusion The presence of estrogen / progesterone receptor in lung cancer can be used to reflect its biological behavior. Combined detection of hormone receptor and DNA content may provide more biological evidence for endocrine therapy and prognosis evaluation of lung cancer